Clinical and Preclinical Evidence for M1 Muscarinic Acetylcholine Receptor Potentiation as a Therapeutic Approach for Rett Syndrome
2022 · Neurotherapeutics · 14 citations
https://doi.org/10.1007/s13311-022-01254-3
S
Sheryl Anne D. Vermudez
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
21
Papers
118
Citations
7
h-index
4
i10-index
Sheryl Anne D. Vermudez is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Genetics and Neurodevelopmental Disorders & Neuroscience and Neuropharmacology Research & Epilepsy research and treatment. The author has an h-index of 7, co-authored 18 publications.
ORCID: 0000-0002-7020-8347Papers by this author
worksGenetic Reduction or Negative Modulation of mGlu<sub>7</sub> Does Not Impact Anxiety and Fear Learning Phenotypes in a Mouse Model of <i>MECP2</i> Duplication Syndrome
2017 · ACS Chemical Neuroscience · 9 citations
https://doi.org/10.1021/acschemneuro.7b00414
Exploration of group II metabotropic glutamate receptor modulation in mouse models of Rett syndrome and MECP2 Duplication syndrome
2022 · Neuropharmacology · 5 citations
https://doi.org/10.1016/j.neuropharm.2022.109022
Overexpression of mGlu7B in Mice: Implications for Neurodevelopmental Disorders
2025 · Molecular Neurobiology · 1 citations
https://doi.org/10.1007/s12035-025-05183-y
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat